Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test
Clinical Benefits of The Enhanced Liver Fibrosis (ELF™) Test
The Enhanced Liver Fibrosis test is a non-invasive blood test that measures three direct markers of fibrosis. Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or liver-related events.
The most widely studied direct marker is the ELF Test which can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH.
Why choose the ELF Test?
Characteristics of an Ideal Non-invasive Liver Fibrosis Test
1. Day J, et al. J Appl Lab Med. 2019 Mar; 3:815-26.
2. Parkes J, et al. Gut. 2010; 59:1245-51.
3. Irvine KM, et al. Liver Int. 2016; 36:370-7.
4. Rosenburg WM, et al. Gastroenterology. 2004; 127:1704-13
5. Nobili, et al. Gastroenterology. 2009; 136:160-7
6. Srivastava A, et al. J Hepatol. 2019; Apr 6: 50168-8278{19}30227-2. doi: 10.1016/j.hep.2019.03.033.
Clinical Benefits of ELF
A simple blood test. Any provider. Any lab.
Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities.1,2
- Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.2,3
- Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events.4
- Enhance patient management with a blood test that facilitates more frequent prognostic assessments
Literature Compendium
This compendium highlights the ELF Test as a prognostic tool in those with advanced fibrosis due to NASH.
Learn more
Did this information help you?
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30.
Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-15.